Effectiveness of Pfizer-BioNTech mRNA Vaccination against COVID-19 Hospitalization among Persons Aged 12–18 Years — United States, June–September 2021

Overcoming COVID-19 Investigators

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

What is already known about this topic? Persons aged 12–18 years are eligible to receive COVID-19 vaccine. Currently, data are lacking on real-world vaccine effectiveness against COVID-19 hospitalization in adolescents. What is added by this report? Among hospitalized U.S. patients aged 12–18 years, vaccine effectiveness of 2 doses of Pfizer-BioNTech vaccine against COVID-19 hospitalization during June–September 2021, was 93% (95% confidence interval = 83%–97%). What are the implications for public health practice? This evaluation demonstrated that 2 doses of Pfizer-BioNTech vaccine were highly effective in preventing COVID-19 hospitalization among persons aged 12–18 years. Findings reinforce the importance of vaccination to protect U.S. youths against severe COVID-19.

Original languageEnglish (US)
Pages (from-to)1483-1488
Number of pages6
JournalMorbidity and Mortality Weekly Report
Volume70
Issue number42
DOIs
StatePublished - 2021
Externally publishedYes

ASJC Scopus subject areas

  • Epidemiology
  • Health(social science)
  • Health, Toxicology and Mutagenesis
  • Health Information Management

Fingerprint

Dive into the research topics of 'Effectiveness of Pfizer-BioNTech mRNA Vaccination against COVID-19 Hospitalization among Persons Aged 12–18 Years — United States, June–September 2021'. Together they form a unique fingerprint.

Cite this